CHCHD2 mutant mice link mitochondrial deficits to PD pathophysiology
Mitochondrial dysfunction is a hallmark of Parkinson's disease (PD), but the mechanisms by which it drives autosomal dominant and idiopathic forms of PD remain unclear. To investigate this, we generated and performed a comprehensive phenotypic analysis of a knock-in mouse model carrying the T61I mutation in the mitochondrial protein CHCHD2 (coiled-coil-helix-coiled-coil-helix domain-containing 2), which causes late-onset symptoms indistinguishable from idiopathic PD. We observed pronounced mitochondrial disruption in substantia nigra dopaminergic neurons, including distorted ultrastructure and CHCHD2 aggregation, as well as disrupted mitochondrial protein-protein interactions in brain lysates. These abnormalities were associated with a whole-body metabolic shift toward glycolysis, elevated mitochondrial reactive oxygen species (ROS), and progressive accumulation of aggregated α-synuclein. In idiopathic PD, <i>CHCHD2</i> gene expression also correlated with α-synuclein levels in vulnerable dopaminergic neurons, and CHCHD2 protein accumulated in early Lewy aggregates. These findings delineate a pathogenic cascade in which CHCHD2 accumulation impairs mitochondrial respiration and increases ROS production, driving α-synuclein aggregation and neurodegeneration.
Authors
- Elyssa B. Margolis (ORCID: https://orcid.org/0000-0001-8777-302X)
- Kirsten Broderick
- Mohamed Taha Moutaoufik (ORCID: https://orcid.org/0000-0002-2013-1601)
- YuHong Fu (ORCID: https://orcid.org/0000-0003-4539-2039)
- Eric J. Huang (ORCID: https://orcid.org/0000-0002-5381-3801)
- Tatiana D. Saccon (ORCID: https://orcid.org/0000-0001-5328-4922)
- Zac Chatterton (ORCID: https://orcid.org/0000-0002-6683-1400)
- Glenda Margaret Halliday (ORCID: https://orcid.org/0000-0003-0422-8398)
- Mai K. Nguyen (ORCID: https://orcid.org/0000-0003-3550-7728)
- Felicia Suteja
- Sadhna Phanse (ORCID: https://orcid.org/0000-0001-6306-0551)
- Giovanni Manfredi (ORCID: https://orcid.org/0000-0003-3893-1348)
- Mohan Babu (ORCID: https://orcid.org/0000-0003-4118-6406)
- Szu-Chi Liao (ORCID: https://orcid.org/0000-0003-2744-363X)
- Kevin McAvoy (ORCID: https://orcid.org/0000-0002-0025-1921)
- Ken Nakamura (ORCID: https://orcid.org/0000-0002-9192-182X)
- Yoshitaka Sei (ORCID: https://orcid.org/0000-0002-4725-8725)
- Kohei Kano (ORCID: https://orcid.org/0000-0002-0223-5781)
- Jonathan X. Meng (ORCID: https://orcid.org/0000-0002-4315-3483)
- H Aoki (ORCID: https://orcid.org/0009-0005-9143-086X)
- Jeffrey A. Simms
Institutions
- The University of Sydney (AU)
- Gladstone Institutes (US)
- University of California, San Francisco (US)
- University of Regina (CA)
- Cornell University (US)
- MIND Research Institute (US)
- Center for Neurosciences (US)
- Université Mohammed VI Polytechnique (MA)
- Research Network (United States) (US)
- Weill Cornell Medicine (US)
- University of California, Berkeley (US)
Publication Details
- Journal
- Science Advances
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1126/sciadv.adu0726
- Citations
- 2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78